| Ytd | 47.17% | |
| 1y | 0.15% |
| Open | Prev Close | 40.06 | Low | High | Mkt Cap | 2.38B | |||
| Vol | 0.00 | Avg Vol | 1.08M | EPS | -7.25 | P/E | -5.53 | Forward P/E | 2.47 |
| Beta | 0.54 | Short Ratio | 5.64 | Inst. Own | 109.29% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-30 | 50-d Avg | 32.66 | 200-d Avg | 31.89 | 1yr Est | 42.63 |
AGIO News
US stock futures up, Nasdaq 100 gains 1%. Danaher Corp (DHR) shares fall 10.1% in pre-market trading
Agios Pharmaceuticals said on Tuesday it will stop development of its sickle cell disease treatmen
Hemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine,
Agios stock surged after FDA granted priority review for mitapivat in sickle cell disease. Mitapivat
Agios stock jumps after the FDA accepts and grants priority review to its sNDA for mitapivat in sick
Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading v
Agios Pharma (AGIO) stock spikes 15% as FDA grants Priority Review for sickle cell disease drug mita
The company took a major step toward an accelerated approval of mitapivat in sickle cell disease tod
RBC Capital analyst Luca Issi maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Sector Perform
Agios stock skyrocketed closer to a profit-taking zone Tuesday after the FDA assigned its sickle cel
US stocks were mixed, Nasdaq fell 1%. DigitalOcean shares rose after strong revenue growth and earni
Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on d
B of A Securities analyst Alec Stranahan maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy
FDA's PDUFA goal date is November 1, 2026 If approved, mitapivat is positioned to become the first o
CAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a co
Agios' shares rose 35% in six months as Aqvesme gains traction, mitapivat expands globally and new I
Agios Pharmaceuticals NASDAQ: AGIO used an investor webcast tied to the 2026 European Hematology Ass
Agios Pharmaceuticals, Inc. (AGIO) Discusses New Data and Strategic Expansion in Rare Hematology at
Mitapivat demonstrated statistically significant improvement in hemoglobin response compared with pl
Agios gains global rights to cevidoplenib for ITP, adding a late-stage rare hematology asset with up
Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic
Agios Pharmaceuticals (NASDAQ:AGIO) has secured exclusive global rights to cevidoplenib, a next-gene
Agios discontinues development of tebapivat in lower-risk MDS after a phase IIb study misses efficac
Agios obtains exclusive global rights to novel, late-stage, next-generation, oral SYK inhibitor Agre
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock?
Agios Pharmaceuticals said on Friday it will stop developing its experimental drug for a form of b
US stocks mixed, energy shares climb. Cleveland-Cliffs falls 6% after reporting Q1 results. Enveric
US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen
During Monday's trading, 1214 companies set new 52-week lows.
Wednesday's session saw 784 companies set new 52-week lows.
On Monday, 721 companies achieved new lows for the year.
On Friday, 209 companies set new 52-week lows.
Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report qu
This morning 533 companies reached new 52-week highs.
On Tuesday, 596 companies set new 52-week highs.